Galena Biopharma Reports Clinical Biomarker Data Demonstrating the Role of NeuVax™ in Preventing Breast Cancer Recurrence

Published: Oct 26, 2012

LAKE OSWEGO, Ore., Oct. 26, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, presented data from the Phase 1/2 clinical trial of NeuVax™ (nelipepimut-S or E75) at the 27th Annual Meeting of the Society for Immunotherapy of Cancer. The event is being held October 26-28, 2012 at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, Maryland.

Back to news